Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aerovate Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AVTE
Nasdaq
8731
https://www.aerovatetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aerovate Therapeutics Inc
Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
- Apr 4th, 2024 5:31 am
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
- Mar 27th, 2024 1:20 pm
Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023
- Mar 27th, 2024 1:01 am
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
- Mar 25th, 2024 8:10 pm
Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)
- Mar 21st, 2024 6:32 am
Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...
- Mar 21st, 2024 6:32 am
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
- Mar 6th, 2024 1:00 pm
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
- Dec 29th, 2023 1:45 pm
Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ...
- Dec 16th, 2023 4:01 pm
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
- Nov 20th, 2023 9:45 pm
Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3
- Nov 13th, 2023 4:09 pm
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
- Nov 13th, 2023 1:00 pm
12 Best Micro Cap Stocks To Invest In
- Oct 30th, 2023 1:32 pm
Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore
- Sep 19th, 2023 9:07 am
TENX: Second Quarter Results
- Aug 28th, 2023 12:20 pm
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
- Aug 14th, 2023 12:00 pm
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
- Jul 22nd, 2023 1:29 pm
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
- Jul 11th, 2023 9:00 pm
TENX: Notice of Allowance Increases Confidence
- Jun 23rd, 2023 10:24 am
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
- Jun 1st, 2023 12:00 pm
Scroll